# Moderna's mRNA vaccine nearly halves the risk of resistant melanoma recurrence

Phase 3 study shows Moderna's mRNA vaccine reduces the risk of resistant melanoma returning.

A study published in Nature shows that Moderna's mRNA vaccine can reduce the risk of recurrence of treatment-resistant melanoma by nearly half. These results come from a phase 3 trial. No further details about the mechanism of action or duration of effectiveness have been reported.

Published: 2026-10-24T07:22:15+00:00
Updated: 2026-10-24T11:56:02+00:00
Verification: unconfirmed

## Sources
- Nature: https://www.nature.com/articles/d41586-026-03417-0